Skip to main content

Table 1 Patient characteristics

From: Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

  No. (%)
Characteristic Diarrhea treated with immunosuppressants, n = 79 Diarrhea without treatment, n = 38 No diarrhea, n = 210 P
Mean age (years, SD) 59.8 (15) 62.2 (12) 59.2 (14) 0.480
Male sex 53 (67) 25 (66) 133 (63) 0.825
Race     < 0.001
 White 75 (95) 32 (84) 154 (73)  
 Other 4 (5) 6 (16) 56 (27)  
Comorbidities present 24 (30) 9 (24) 62 (30) 0.733
Underlying autoimmune disorder 4 (5) 1 (3) 13 (6) 0.663
History of smoking 36 (46) 20 (53) 107 (51) 0.671
History of use of nonsteroidal anti-inflammatory agents 38 (48) 15 (39) 80 (38) 0.300
ECOG performance status     0.070
 0–2 78 (99) 38 (100) 197 (94)  
 3–4 1 (1) 0 (0) 13 (6)  
Malignancy type     < 0.001
 Melanoma 55 (70) 9 (24) 56 (27)  
 Solid tumor 23 (29) 14 (37) 111 (53)  
 Hematologic 1 (1) 15 (39) 43 (20)  
Cancer Stagea     < 0.001
 Stage III 16 (21) 2 (9) 7 (4)  
 Stage IV 61 (79) 21 (91) 149 (96)  
Colitis grade 2–3 49 (62)
Checkpoint inhibitor type     < 0.001
 Ipilimumab 48 (61) 23 (61) 67 (32)  
 Nivolumab 5 (6) 8 (21) 87 (41)  
 Pembrolizumab 13 (16) 6 (16) 50 (24)  
 Combinationb 12 (15) 1 (3) 6 (3)  
 Atezolizumab 1 (1) 0 (0) 0 (0)  
  1. Abbreviations: ECOG, Eastern Cooperative Oncology Group; SD, standard deviation
  2. aThe American Joint Committee on Cancer staging system was used. Stage was known in 77 patients in the immunosuppressant group, 23 in the untreated diarrhea group, and 156 in the no diarrhea group
  3. bCombination therapy consisted of ipilimumab + nivolumab